Outlook Therapeutics Q1 loss widens to $18.7M; PDUFA goal date August 29, 2023

Outlook Therapeutics, Inc.

2023-Q1 EPS reported -$0.08

Net loss $18.7M ($0.08/share) vs $14.5M ($0.08) in Q1 fiscal 2022.
Cash and equivalents $52.3M; raised $24M equity and $30M convertible note in Dec 2022.
FDA PDUFA goal date for ONS-5010 (wet AMD) set for August 29, 2023.
Pre-launch commercial activities underway; partnership with AmerisourceBergen.
EMA MAA accepted for ONS-5010; decision expected early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Outlook Therapeutics, Inc. reported fiscal first quarter ended December 31, 2022 results: net income $18.7 million, or $0.08 per basic and diluted share, EPS $0.08 per basic and diluted share.

Period: fiscal first quarter ended December 31, 2022
Net income: $18.7 million, or $0.08 per basic and diluted share
EPS: $0.08 per basic and diluted share
Result: reported results

Exact text from the filing

On February 14, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-020751

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.